Designing and Evaluation of Novel Valproic Acid Derivatives by IvLCB: In-vitro Like Computational Bioassay, Predictive Toxicological Study & Docking Analysis for GABA-A Mediated Inhibition of Neural Firing

Muskan Alvi¹, Vikash Pal¹, Sahil Kumar¹, Yash Kumar¹, Ajeet ^1, , Babita Kumar¹, Shabnam Ain¹ and Qurratul Ain¹

¹Department of Medicinal Chemistry & Drug Design, Sanskar College of Pharmacy and Research, Ghaziabad, India

Cite this paper:
Muskan Alvi, Vikash Pal, Sahil Kumar, Yash Kumar, Ajeet , Babita Kumar, Shabnam Ain and Qurratul Ain. Designing and Evaluation of Novel Valproic Acid Derivatives by IvLCB: In-vitro Like Computational Bioassay, Predictive Toxicological Study & Docking Analysis for GABA-A Mediated Inhibition of Neural Firing. American Journal of Pharmacological Sciences. 2025; 13(1):19-32. doi: 10.12691/ajps-13-1-3

Abstract

Gamma-aminobutyric acid (GABA) is the brain's primary inhibitory neurotransmitter, and some anti-epileptic drugs work by enhancing its effects. Medications such as Valproic acid and Benzodiazepines increase GABA activity, which inhibits neural firing and suppresses seizure activity. In the present study twelve Valproic acid derivatives were designed and evaluated for their GABA-A mediated inhibition of neural firing by in-silico methods. All novel designed molecules were evaluated by IvLCB: In-vitro like computational bioassay and SwissDock. These molecules were also evaluated for their in-silico biological activity spectrum & predictive toxicological study by MolpredictX and predictive bioactivity score by Molinspiration. As per the analysis performed it was found that designed molecule VAL1 shows strong binding ability to PDB ID: 4COF with 3 hydrogen bonds and binding affinity of -4.4 kcal/mol.

Keywords:
GABA-A Valproic acid derivatives computational study docking in-silico analysis in-vitro like computational bioassay

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Alison Hitchcock, Frank Vajda, John Craig, Terence J. O’Brien, Arjune Sen, Development of EpiRisk: An online clinical tool for estimating the risk of major congenital malformations in pregnant women treated for epilepsy, Epilepsia Open, 2018, 281-285.
[2]	Juseop Kang, Yoo-Sin Park, Shin-Hee Kim, Sang-Hyun Kim, and Min-Young Jun, Modern Methods for Analysis of Antiepileptic Drugs in the Biological Fluids for Pharmacokinetics, Bioequivalence and Therapeutic Drug Monitoring, Korean J Physiol Pharmacol, Vol 15 67－81, April, 2011.
[3]	Robert L. Macdonald and Kevin M. Kelly, Antiepileptic Drug Mechanisms of Action, Epilepsia 1995, S2-S12.
[4]	Kinga K. Borowicz-Reutt, Effects of Antiarrhythmic Drugs on Antiepileptic Drug Action—A Critical Review of Experimental Findings, MDPI, Poland, 2022.
[5]	Barbara Miziak, Agnieszka Konarzewska, Marzena Ułamek-Kozioł, Monika Dudra-Jastrz˛ ebska, Ryszard Pluta, Stanisław J. Czuczwar, Anti-Epileptogenic Effects of Antiepileptic Drugs, MDPI, Poland, 2020.
[6]	Jarogniew J. Luszczki, Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions,Pharmacological Reports, Poland, 197-216, 2009.
[7]	H. Zhou, N. Wang, L. Xu, H.-L. Huang, C.-Y. Yu, Clinical study on anti-epileptic drug with B vitamins for the treatment of epilepsy after stroke, European Review for Medical and Pharmacological Sciences, China, 2017.
[8]	Rowena M. A. Packer, Luisa De Risio and Holger A. Volk, Investigating the potential of the anti_epileptic drug imepitoin as a treatment for co-morbid anxiety in dogs with idiopathic epilepsy, BMC Veterinary Research, Hertfordshire, 2017.
[9]	Emilio Perucca, H. Steve White, Meir Bialer, New GABATargeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development, CNS Drugs, august 2023.
[10]	Sanjay M. Sisodiya, Precision medicine and therapies of the future, Epilepsia, Bucks UK, 2020.
[11]	Carlos A. M. Guerreiro, Epilepsy: Is there hope?, Indian J Med Res, Brazil, 2016.
[12]	Enes Akyüz, Betul koklu, Cansu Ozenen, Alina Arulsamy and Mohd. Farooq Shaikh, Elucidating the Potential Side Effects of Current Anti-Seizure Drugs for Epilepsy, Bentham Science Publishers, Turkey, 2021.
[13]	Ngonidzashe Mutanana, Maria Tsvere, Manase K. Chiweshe, General side effects and challenges associated with anti-epilepsy medication: A review of related literature, AOSIS Publishers, Zimbabwe, 2020.
[14]	Michele Simonato, Amy R Brooks-Kayal, Jerome Engel Jr, Aristea S Galanopoulou, Frances E Jensen, Solomon L Moshe, et al. The challenge and promise of anti-epileptic therapy development in animal models, USA, 2016.
[15]	Asher Ornoy, Boniface Echefu, Maria Becker, Valproic Acid in Pregnancy Revisited: Neurobehavioral, Biochemical and Molecular Changes Affecting the Embryo and Fetus in Humans and in Animals: A Narrative Review, MDPI, Israel, 2023.
[16]	Sarah J Nevitt, Maria Sudell, Sofia Cividini, Anthony G Marson, Catrin Tudur Smith, Antiepileptic drug monotherapy for epilepsy: a network meta_analysis of individual participant data, Cochrane Library, Liverpool, UK, 2022.
[17]	Leonardo G. Ferreira, Ricardo N. dos Santos, Glaucius Oliva and Adriano D. Andricopulo, Molecular Docking and Structure-Based Drug Design Strategies, MPDI, Brazil, 2015.
[18]	Joseph M. Paggi, Ayush Pandit, Ron O. Dror, The Art and Science of Molecular Docking, annual review of biochemistry, volume 93, 2024.
[19]	Azar Asadollahi, Mehdi Asadi, Faezeh Sadat Hosseini, Zeinab Ekhtiari, Mahmood Biglar, and Massoud Amanlou, Synthesis, molecular docking, and antiepileptic activity of novel phthalimide derivatives bearing amino acid conjugated anilines, Research in Pharmaceutical Sciences, iran, 2019.
[20]	Sora An, Chaewon Kang, Hyang Woon Lee, Artificial Intelligence and Computational Approaches for Epilepsy, Journal of Epilepsy Research, korea, 2020.
[21]	Xiaoying Lv, JiaWang, YingYuan, Lurong Pan, Qi Liu, JinjiangGuo, In-Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy, Scientifc Reports, China, 2024.
[22]	Bugnon M, Röhrig UF, Goullieux M, Perez MAS, Daina A, Michielin O, Zoete V. SwissDock 2024: major enhancements for small-molecule docking with Attracting Cavities and AutoDock Vina. Nucleic Acids Res. 2024.
[23]	Eberhardt J, Santos-Martins D, Tillack AF, Forli S.. AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. J. Chem. Inf. Model., 2021.
[24]	Ajeet, Kumar A., Mishra A. K., “Design, molecular docking, synthesis, characterization, biological activity evaluation (against MES model), in-silico biological activity spectrum (PASS analysis), toxicological and predicted oral rat LD50 studies of novel sulphonamide derivatives”, Frontiers in Biology, Springer Nature, 13. 425-451.2018.
[25]	Maurya P. P., Ajeet., “4-Aminoquinazoline-6, 7-diol Derivatives for Enhanced EGFR Binding (as Inhibitor) Against Lung Cancer”, Letters in Applied NanoBioSciences, 13(4). 1-12. 2024.